Posts by: Alejandra Viviescas PhD

Alejandra Viviescas PhD

Alejandra has a PhD in Genetics from São Paulo State University (UNESP) and currently acts as a scientific writer, editor, and translator. As a writer for BioNews, she fulfills her passion for making scientific data available and understandable to the general public. Besides BioNews, she works as a language editor for non-English speaking authors and as an author of science books for kids.

November 27, 2019November 27, 2019

IGF2R Blood Levels May Help Predict Antibiotic Response in CF Pulmonary Exacerbations, Study Says

cystic fibrosis, News

Measuring the levels of insulin-like growth factor 2 receptor (IGF2R) during the first days of treatment with intravenous antibiotics could help predict treatment response in cystic fibrosis patients experiencing pulmonary ... Read more

October 18, 2019October 18, 2019

First Patients Dosed in Trial Testing MS1819-SD Plus PERT for CF-related Severe EPI, AzurRX Says

cystic fibrosis, News

AzurRx BioPharma has started dosing patients in a Phase 2 clinical trial assessing its investigational therapy MS1819-SD in combination with porcine enzyme replacement therapy (PERT) for people with cystic fibrosis ... Read more

October 11, 2019October 11, 2019

Viral Respiratory Tract Infections in Young CF Children Usually Mild, Study Found

cystic fibrosis, News

Viral respiratory tract infections in young children with cystic fibrosis tend to be mild and not require hospitalization, a study found. Infections caused by respiratory syncytial virus (RSV) were rare ... Read more

August 16, 2019August 16, 2019

High Liver Enzyme Levels Linked to Risk of CF-Related Diabetes, Especially in Men, Study Finds

cystic fibrosis, News

High blood levels of the enzyme alanine aminotransferase (ALT) — a biomarker of liver damage — might indicate a higher risk of rising blood sugar levels and cystic fibrosis-related diabetes (CFRD), ... Read more

August 8, 2019September 18, 2019

CF Foundation Earmarks Up to $15M for Arcturus Therapeutics to Advance Experimental RNA Therapy

cystic fibrosis, News

The Cystic Fibrosis Foundation (CFF) will give up to $15 million to Arcturus Therapeutics to advance the development of an experimental RNA therapy, called LUNAR-CF, to treat CF patients with all types ... Read more

June 18, 2019June 18, 2019

Kalydeco Shows Long-term Efficacy in CF Patients in Real-world Setting

cystic fibrosis, News

Kalydeco (ivacaftor) preserved lung function, improved the nutritional status, and reduced hospital visits and chronic bacterial infections in people with cystic fibrosis (CF) when administered for up to five years in ... Read more

June 12, 2019August 5, 2019

Inhaled Imipenem/cilastatin an Alternative Treatment for Lung Infection in Children with CF, Case Reports Show

cystic fibrosis, News

The inhaled formulation of broad-spectrum antibiotics such as imipenem/cilastatin is a useful alternative to treat chronic lung bacterial infections in children with cystic fibrosis (CF) because it causes fewer side effects, ... Read more

June 11, 2019August 2, 2019

Kalydeco Restored Pancreatic Function in Boy with CF, Case Report Suggests

cystic fibrosis, News

A case report about a 10-year-old boy suggests that Vertex Pharmaceuticals‘ Kalydeco (ivacaftor) can restore the function of the pancreas and the production of pancreatic enzymes in children with cystic ... Read more

May 20, 2019May 20, 2019

Vivus Announces Partnership with HarborPath to Make Pancreaze Available to Uninsured Patients

cystic fibrosis, News

Vivus recently announced a partnership with HarborPath Direct to facilitate access to Pancreaze (pancrelipase) for eligible patients who do not have health insurance or are underinsured. The treatment will be available ... Read more

May 14, 2019May 14, 2019

Phages, Viruses that Attack Bacteria, Are a Potential Therapy Against Infections, Case Report Suggests

cystic fibrosis, News

The case report of a cystic fibrosis (CF) patient suggests that phages — viruses that naturally infect and kill bacteria — are a potential personalized therapy against infections caused by ... Read more

Join our email list!